Crick
HomeTrialsGenesDrugs23andMeGraphBlogContact
  • Home
  • Trials
  • Genes
  • Drugs
  • 23andMe
  • Graph
  • Blog
  • Contact
Crick

An open-source clinical intelligence platform. Explore clinical trials, gene networks, and molecular structures using public data sources.

Data Sources

  • ClinicalTrials.gov
  • OpenTargets
  • ClinVar
  • PubChem

Links

  • Contact
  • About
  • Privacy

© 2026 Crick. All rights reserved.

Crick is for educational purposes only. Not medical advice.

Results for “Neovascular Age-Related Macular Degeneration (nAMD)”

135 trials

Showing 20 of 135 results

Large-scale testing (Phase 3)WithdrawnNCT04697953
What this trial is testing

Efficacy and Safety of Brolucizumab 6mg in a Treat and Extend Regimen in Patients With Neovascular Age-Related Macular Degeneration (nAMD) With Prior Anti-VEGF Exposure (PEREGRINE)

Who this might be right for
Age-related Macular Degeneration (AMD)
Novartis Pharmaceuticals
Testing effectiveness (Phase 2)Study completedNCT03066258
What this trial is testing

Safety and Tolerability of RGX-314 (Investigational Product) Gene Therapy for Neovascular AMD Trial

Who this might be right for
Neovascular Age-related Macular DegenerationWet Age-related Macular Degeneration
REGENXBIO Inc. 42
Large-scale testing (Phase 3)Study completedNCT03823300
What this trial is testing

Evaluate the Efficacy and Safety of Faricimab in Participants With Neovascular Age-Related Macular Degeneration (LUCERNE)

Who this might be right for
Wet Macular Degeneration
Hoffmann-La Roche 658
Not applicableEnded earlyNCT04764656
What this trial is testing

Observational Study to Evaluate Fluid Resolution and Effectiveness of Brolucizumab for nAMD in Portugal

Who this might be right for
Neovascular Age-related Macular Degeneration (nAMD)
Novartis Pharmaceuticals 81
Post-approval studies (Phase 4)Study completedNCT05269966
What this trial is testing

Study to Evaluate the Safety and Effectiveness of Intravitreal Injections (IVI) of Brolucizumab in Patients With Neovascular Age-related Macular Degeneration (nAMD)

Who this might be right for
Neovascular Age-related Macular Degeneration (nAMD)
Novartis Pharmaceuticals 105
Early research (Phase 1)Active Not RecruitingNCT05903794
What this trial is testing

EXG102-031 in Patients With wAMD (Everest)

Who this might be right for
Neovascular (Wet) Age-related Macular Degeneration (nAMD)
Exegenesis Bio 12
Testing effectiveness (Phase 2)Looking for participantsNCT06487039
What this trial is testing

Trial to Evaluate the Safety and Efficacy of EB-203 in Patients With Neovascular Age-related Macular Degeneration

Who this might be right for
Neovascular Age-related Macular Degeneration (nAMD)
EyebioKorea, Inc. 50
Large-scale testing (Phase 3)Not Yet RecruitingNCT07129239
What this trial is testing

High Dose (HD) Aflibercept Switch in Neovascular Age-related Macular Degeneration (nAMD): to Load or Maintain (HEIRLOOM)

Who this might be right for
Wet Age-related Macular Degeneration (wAMD)
Clinique de Retine de l'est 180
Testing effectiveness (Phase 2)Study completedNCT02507388
What this trial is testing

Safety and Pharmacokinetics of RTH258 in Subjects With Age-Related Macular Degeneration

Who this might be right for
Neovascular Age-Related Macular Degeneration
Alcon Research 51
Not applicableLooking for participantsNCT06346600
What this trial is testing

A Long-term Follow-up Study to Evaluate SKG0106 in the Treatment of Patients With nAMD

Who this might be right for
Neovascular (Wet) Age-related Macular Degeneration
Skyline Therapeutics 83
Large-scale testing (Phase 3)Looking for participantsNCT06847542
What this trial is testing

36-Week Refill Exchanges of Port Delivery System (PDS) With Ranibizumab in nAMD

Who this might be right for
Neovascular Age-related Macular Degeneration
Hoffmann-La Roche 250
Not applicableStudy completedNCT04847895
What this trial is testing

Observation of Treatment Patterns With Lucentis® in Real-life Conditions in All Approved Indications

Who this might be right for
Neovascular (Wet) Age-related Macular Degeneration
Novartis Pharmaceuticals 5,500
Not applicableStudy completedNCT06769412
What this trial is testing

A Real-World Evidence Study for the Incidence of Retinal Vasculitis (RV) Among Adult Patients Receiving Aflibercept 2 mg in the United States (US)

Who this might be right for
Retinal Vasculitis
Regeneron Pharmaceuticals 550,000
Not applicableNot Yet RecruitingNCT07088445
What this trial is testing

Therapeutic Prospects of Faricimab Injection for Patients Affected by Neovascular Age-Related Macular Degeneration

Who this might be right for
Neovascular Age-related Macular Degeneration(nAMD)
Hui Peng 35
Not applicableStudy completedNCT05131646
What this trial is testing

Extension Study to Evaluate the Long-term Outcomes of Subjects in the CLS-AX CLS1002-101 Study

Who this might be right for
Neovascular Age-related Macular Degeneration
Clearside Biomedical, Inc. 15
Not applicableStudy completedNCT05834075
What this trial is testing

A Retrospective Study to Evaluate the Early Real-world Evidence of Brolucizumab in Patients With Neovascular Age-related Macular Degeneration (nAMD) in India

Who this might be right for
Neurovascular Age-related Macular Degeneration
Novartis Pharmaceuticals 63
Post-approval studies (Phase 4)Study completedNCT01775124
What this trial is testing

Efficacy and Safety of Ranibizumab 0.5 mg Administered as Two Alternative Dosing Regimens in Chinese Patients With nAMD (Age Related Macular Degeneration)

Who this might be right for
Neovascular Age-related Macular Degeneration
Novartis Pharmaceuticals 332
Testing effectiveness (Phase 2)Looking for participantsNCT06141460
What this trial is testing

Safety and Efficacy of RRG001 Gene Therapy in Subjects With Neovascular Age-related Macular Degeneration (nAMD)

Who this might be right for
Neovascular Age-related Macular Degeneration
Shanghai Refreshgene Technology Co., Ltd. 48
Large-scale testing (Phase 3)Active Not RecruitingNCT04657289
What this trial is testing

The Efficacy, Safety, and Pharmacokinetics of a 36-Week Refill Regimen for the Port Delivery System With Ranibizumab in Patients With Neovascular Age-Related Macular Degeneration (Velodrome)

Who this might be right for
Neovascular Age-related Macular Degeneration (nAMD)
Hoffmann-La Roche 451
Testing effectiveness (Phase 2)UnknownNCT05390840
What this trial is testing

Investigate the Effect on Central Macular Thickness of Treatment With MG-O-1002 Eye Drops in Participants Aged Over 45 With Neovascular Age-related Macular Degeneration (nAMD)

Who this might be right for
Age-Related Macular Degeneration
Theratocular Biotek Co. 36
Load More Results

Filters

Phase
Early Phase 1
Phase 1
Phase 2
Phase 3
Phase 4
Status
Recruiting
Active, Not Recruiting
Not Yet Recruiting
Completed
Enrolling by Invitation